Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Non-cash Items (2023 - 2025)

Contineum Therapeutics has reported Non-cash Items over the past 3 years, most recently at $2.7 million for Q3 2025.

  • Quarterly results put Non-cash Items at $2.7 million for Q3 2025, down 92.95% from a year ago — trailing twelve months through Sep 2025 was $2.7 million (down 92.95% YoY), and the annual figure for FY2024 was $21.5 million, up 44.21%.
  • Non-cash Items for Q3 2025 was $2.7 million at Contineum Therapeutics, up from $2.6 million in the prior quarter.
  • Over the last five years, Non-cash Items for CTNM hit a ceiling of $39.0 million in Q3 2024 and a floor of $1.9 million in Q2 2024.
  • Median Non-cash Items over the past 3 years was $10.4 million (2023), compared with a mean of $14.5 million.
  • Biggest five-year swings in Non-cash Items: skyrocketed 44.21% in 2024 and later crashed 92.95% in 2025.
  • Contineum Therapeutics' Non-cash Items stood at $14.9 million in 2023, then surged by 44.21% to $21.5 million in 2024, then plummeted by 87.19% to $2.7 million in 2025.
  • The last three reported values for Non-cash Items were $2.7 million (Q3 2025), $2.6 million (Q2 2025), and $5.9 million (Q1 2025) per Business Quant data.